Liquid biopsy: a new weapon for molecular changes of neoplasia

Università degli Studi della Campania
October 02 2017
Position Type
Full Time
Organization Type

Liquid biopsy can become fundamental to find circulating non-invasive biomarkers useful for the therapeutic management of the tumor. Indeed, genomic mutations vary not only from patient to patient, but also in the same patient during the treatment and this represents a pivotal challenge in cancer treatment, especially in an age of “precision medicine”. The determination of predictive biomarkers of response allows the immediate change of the therapeutic strategy with the selection of a more appropriate intervention. The objective of the present study is to evaluate the occurrence of the mutation of Epidermal Growth Factor Receptor (EGFR) T790M on plasma of patients with non small cell lung cancer in order to both predict resistance to anti-EGFR Tyrosine Kinase Inhibitors (TKIs) and to change the therapy with second generation TKIs

This job comes from a partnership with Science Magazine and Euraxess